XOMA Corporation (NASDAQ:XOMA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Tuesday. They currently have a $38.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective indicates a potential upside of 58.80% from the company’s current price.

Several other equities analysts also recently commented on XOMA. ValuEngine raised XOMA Corporation from a “strong sell” rating to a “sell” rating in a research report on Wednesday, July 12th. Zacks Investment Research raised XOMA Corporation from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Friday, July 14th. Finally, Wedbush reaffirmed a “hold” rating on shares of XOMA Corporation in a research report on Monday, August 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $27.33.

Shares of XOMA Corporation (XOMA) opened at 23.93 on Tuesday. XOMA Corporation has a 1-year low of $3.96 and a 1-year high of $24.92. The company has a 50 day moving average of $19.34 and a 200 day moving average of $10.13. The company’s market cap is $181.82 million.

TRADEMARK VIOLATION NOTICE: This article was first published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/hc-wainwright-reiterates-buy-rating-for-xoma-corporation-xoma/1640685.html.

An institutional investor recently raised its position in XOMA Corporation stock. California Public Employees Retirement System lifted its stake in XOMA Corporation (NASDAQ:XOMA) by 95.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 21,780 shares of the biotechnology company’s stock after buying an additional 10,640 shares during the period. California Public Employees Retirement System owned approximately 0.29% of XOMA Corporation worth $123,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 32.92% of the company’s stock.

XOMA Corporation Company Profile

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.